Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Debiopharm to end licensing deal with Japanese venture

This article was originally published in Scrip

Executive Summary

Debiopharm has decided to terminate a technology licensing deal with the Japanese drug delivery venture NanoCarrier following a review of strategic development priorities.

You may also be interested in...



Japan Enhertu Nod Another Boost For Daiichi's Oncology Hopes

Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.

GTS Alliance Gives Mochida A Cell Therapy Buy-In

Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.

Positive Evidence Stacks Up For Takeda's Dengue Vaccine

New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.

Topics

Related Companies

UsernamePublicRestriction

Register

SC010217

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel